tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2022 Nov 30.
doi: 10.1111/irv.13072. Online ahead of print.
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months
Francesca L Mordant[SUP] 1 [/SUP], Olivia H Price[SUP] 2 [/SUP], Rajeev Rudraraju[SUP] 1 [/SUP], Monica A Slavin[SUP] 3 4 5 6 [/SUP], Caroline Marshall[SUP] 6 7 [/SUP], Leon J Worth[SUP] 3 4 8 [/SUP], Heidi Peck[SUP] 2 [/SUP], Ian G Barr[SUP] 1 2 [/SUP], Sheena G Sullivan[SUP] 2 6 [/SUP], Kanta Subbarao[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: In Australia, seasonal inactivated influenza vaccine is typically offered in April. However, the onset, peak and end of a typical influenza season vary, and optimal timing for vaccination remains unclear. Here, we investigated vaccine-induced antibody response kinetics over 6 months in different age groups.
Methods: We conducted a prospective serosurvey among 71 adults aged 18-50 years, 15 community-dwelling ('healthy') and 16 aged-care facility resident ('frail') older adults aged ≥65 years who received the 2018 southern hemisphere vaccines. Sera were collected at baseline, and 1, 2, 4, and 6 months post-vaccination. Antibody titres were measured by haemagglutination inhibition or microneutralisation assays. Geometric mean titres were estimated using random effects regression modelling and superimposed on 2014-2018 influenza season epidemic curves.
Results: Antibody titres peaked 1.2-1.3 months post-vaccination for all viruses, declined by 3 months post-vaccination but, notably, persisted above baseline after 6 months in all age groups by 1.3- to 1.5-fold against A(H1N1)pdm09, 1.7- to 2-fold against A(H3N2), 1.7- to 2.1-fold against B/Yamagata and 1.8-fold against B/Victoria. Antibody kinetics were similar among different age groups. Antibody responses were poor against cell-culture grown compared to egg-grown viruses.
Conclusions: These results suggest subtype-specific antibody-mediated protection persists for at least 6 months, which corresponds to the duration of a typical influenza season.
Keywords: antibody; influenza; kinetics; serosurvey; vaccine.
. 2022 Nov 30.
doi: 10.1111/irv.13072. Online ahead of print.
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months
Francesca L Mordant[SUP] 1 [/SUP], Olivia H Price[SUP] 2 [/SUP], Rajeev Rudraraju[SUP] 1 [/SUP], Monica A Slavin[SUP] 3 4 5 6 [/SUP], Caroline Marshall[SUP] 6 7 [/SUP], Leon J Worth[SUP] 3 4 8 [/SUP], Heidi Peck[SUP] 2 [/SUP], Ian G Barr[SUP] 1 2 [/SUP], Sheena G Sullivan[SUP] 2 6 [/SUP], Kanta Subbarao[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36451293
- DOI: 10.1111/irv.13072
Abstract
Background: In Australia, seasonal inactivated influenza vaccine is typically offered in April. However, the onset, peak and end of a typical influenza season vary, and optimal timing for vaccination remains unclear. Here, we investigated vaccine-induced antibody response kinetics over 6 months in different age groups.
Methods: We conducted a prospective serosurvey among 71 adults aged 18-50 years, 15 community-dwelling ('healthy') and 16 aged-care facility resident ('frail') older adults aged ≥65 years who received the 2018 southern hemisphere vaccines. Sera were collected at baseline, and 1, 2, 4, and 6 months post-vaccination. Antibody titres were measured by haemagglutination inhibition or microneutralisation assays. Geometric mean titres were estimated using random effects regression modelling and superimposed on 2014-2018 influenza season epidemic curves.
Results: Antibody titres peaked 1.2-1.3 months post-vaccination for all viruses, declined by 3 months post-vaccination but, notably, persisted above baseline after 6 months in all age groups by 1.3- to 1.5-fold against A(H1N1)pdm09, 1.7- to 2-fold against A(H3N2), 1.7- to 2.1-fold against B/Yamagata and 1.8-fold against B/Victoria. Antibody kinetics were similar among different age groups. Antibody responses were poor against cell-culture grown compared to egg-grown viruses.
Conclusions: These results suggest subtype-specific antibody-mediated protection persists for at least 6 months, which corresponds to the duration of a typical influenza season.
Keywords: antibody; influenza; kinetics; serosurvey; vaccine.